The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS). PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven […]
Always Be a Step Ahead
Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.
Subscribe to AMI's Insights Newsletter Today.